Candida parapsilosis sensu lato in pediatric patients. Identification of cryptic species and antifungal susceptibility testing.

Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis (2008) 20.88

The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis (2005) 5.25

Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene. Microbiology (1997) 5.22

Epidemiology of invasive mycoses in North America. Crit Rev Microbiol (2010) 4.06

Candida orthopsilosis and Candida metapsilosis spp. nov. to replace Candida parapsilosis groups II and III. J Clin Microbiol (2005) 3.93

Candida parapsilosis, an emerging fungal pathogen. Clin Microbiol Rev (2008) 3.52

Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012. J Clin Microbiol (2012) 2.82

Interlaboratory variability of Caspofungin MICs for Candida spp. Using CLSI and EUCAST methods: should the clinical laboratory be testing this agent? Antimicrob Agents Chemother (2013) 2.14

National surveillance of fungemia in Denmark (2004 to 2009). J Clin Microbiol (2010) 2.10

One year prospective survey of Candida bloodstream infections in Scotland. J Med Microbiol (2007) 1.87

Geographic distribution and antifungal susceptibility of the newly described species Candida orthopsilosis and Candida metapsilosis in comparison to the closely related species Candida parapsilosis. J Clin Microbiol (2008) 1.66

Minimum fungicidal concentrations of amphotericin B for bloodstream Candida species. Diagn Microbiol Infect Dis (2003) 1.54

Epidemiology of candidemia at a Children's hospital, 2002 to 2006. Pediatr Infect Dis J (2009) 1.30

Prevalence and susceptibility profile of Candida metapsilosis and Candida orthopsilosis: results from population-based surveillance of candidemia in Spain. Antimicrob Agents Chemother (2008) 1.29

Prevalence, distribution, and antifungal susceptibility profiles of Candida parapsilosis, C. orthopsilosis, and C. metapsilosis in a tertiary care hospital. J Clin Microbiol (2009) 1.27

Not just little adults: candidemia epidemiology, molecular characterization, and antifungal susceptibility in neonatal and pediatric patients. Pediatrics (2009) 1.25

Prospective multicenter study of the epidemiology, molecular identification, and antifungal susceptibility of Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis isolated from patients with candidemia. Antimicrob Agents Chemother (2011) 1.17

Amphotericin B tolerance: a characteristic of Candida parapsilosis not shared by other Candida species. J Infect Dis (1983) 1.13

Species distribution and susceptibility profile of yeasts isolated from blood cultures: results of a multicenter active laboratory-based surveillance study in Argentina. Rev Argent Microbiol (2012) 1.00

Prevalence rates and antifungal susceptibility profiles of the Candida parapsilosis species complex: results from a nationwide surveillance of candidaemia in Brazil. Clin Microbiol Infect (2009) 0.97

Assessment of two new molecular methods for identification of Candida parapsilosis sensu lato species. J Clin Microbiol (2011) 0.97

Differential in vitro activity of anidulafungin, caspofungin and micafungin against Candida parapsilosis isolates recovered from a burn unit. Clin Microbiol Infect (2009) 0.97

Characterization of Candida parapsilosis complex isolates. Clin Microbiol Infect (2011) 0.94

Candidemia by species of the Candida parapsilosis complex in children's hospital: prevalence, biofilm production and antifungal susceptibility. Mycopathologia (2013) 0.93

Changing spectrum of invasive candidiasis and its therapeutic implications. Clin Microbiol Infect (2001) 0.86

Molecular epidemiology and antifungal susceptibility of Candida parapsilosis sensu stricto, Candida orthopsilosis, and Candida metapsilosis in Taiwan. Diagn Microbiol Infect Dis (2010) 0.85

Molecular characterization and antifungal susceptibility of the Candida parapsilosis species complex of clinical isolates from Monterrey, Mexico. Med Mycol (2012) 0.82

New milk medium for germ tube and chlamydoconidia production by Candida albicans. Mycopathologia (1993) 0.81

Species distribution and antifungal susceptibility of bloodstream fungal isolates in paediatric patients in Mexico: a nationwide surveillance study. J Antimicrob Chemother (2013) 0.80

Candida parapsilosis (sensu lato) isolated from hospitals located in the Southeast of Brazil: Species distribution, antifungal susceptibility and virulence attributes. Int J Med Microbiol (2015) 0.79

[Age group, geographical incidence and patterns of antifungal susceptibility of Candida species causing candidemia in the Spanish paediatric population]. Enferm Infecc Microbiol Clin (2013) 0.78

[Epidemiology of fungaemia in a paediatric hospital of high complexity]. Rev Iberoam Micol (2010) 0.76